Zydus dedicated to life

Press Release Press Release Press Release Press Release Press Release Press Release Press Release Press Release

Zydus Cadila receives final approval from USFDA for Potassium Chloride Extended-Release Tablets

Ahmedabad, 18 September, 2020

Zydus Cadila has received final approval from the USFDA to market Potassium Chloride Extended-Release Tablets (US RLD: K-Dur Extended-Release Tablets) in the strengths of 10 mEq (750 mg) and 20 mEq (1500 mg).

The medication is a mineral supplement used to treat or prevent low amounts of potassium in the blood and will be manufactured at the group's formulation manufacturing facility at the SEZ, Ahmedabad.

The group now has 301 approvals and has so far filed over 390 ANDAs since the commencement of the filing process in FY 2003-04.

About Zydus Cadila

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies. The group employs nearly 25000 people worldwide and is dedicated to creating healthier communities globally.

***

For further information please contact :
The Corporate Communications Department

Cadila Healthcare Limited
Regd. Office : 'Zydus Corporate Park', Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar), Nr. Vaishnodevi Circle, S. G. Highway, Ahmedabad 382 481, India.
Phone : +91-079-71800000, +91-079-48040000 www.zyduscadila.com
CIN : L24230GJ1995PLC025878